A Proof‐of‐Concept Study of Short‐Cycle Intermittent Antiretroviral Therapy with a Once‐Daily Regimen of Didanosine, Lamivudine, and Efavirenz for the Treatment of Chronic HIV Infection | Zendy

Mark Dybul | Zendy; Elizabeth NiesKraske | Zendy; Robin Dewar | Zendy; Frank Maldarelli | Zendy; Claire W. Hallahan | Zendy; Marybeth Daucher | Zendy; Stephen C. Piscitelli | Zendy; Linda A. Ehler | Zendy; Ann Weigand | Zendy; Sarah Palmer | Zendy; Julia A. Metcalf | Zendy; Richard T. Davey | Zendy; Diane M. Rock Kress | Zendy; April Powers | Zendy; Ingrid A. Beck | Zendy; Lisa M. Frenkel | Zendy; Michael Baseler | Zendy; John M. Coffin | Zendy; Anthony S. Fauci | Zendy

Open Access

A Proof‐of‐Concept Study of Short‐Cycle Intermittent Antiretroviral Therapy with a Once‐Daily Regimen of Didanosine, Lamivudine, and Efavirenz for the Treatment of Chronic HIV Infection

Author(s) -

Mark Dybul,

Elizabeth NiesKraske,

Robin Dewar,

Frank Maldarelli,

Claire W. Hallahan,

Marybeth Daucher,

Stephen C. Piscitelli,

Linda A. Ehler,

Ann Weigand,

Sarah Palmer,

Julia A. Metcalf,

Richard T. Davey,

Diane M. Rock Kress,

April Powers,

Ingrid A. Beck,

Lisa M. Frenkel,

Michael Baseler,

John M. Coffin,

Anthony S. Fauci

Publication year - 2004

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/386344

Subject(s) - didanosine , efavirenz , lamivudine , medicine , regimen , human immunodeficiency virus (hiv) , pharmacotherapy , antiretroviral treatment , viremia , antiretroviral therapy , pharmacology , viral load , virology , chronic hepatitis , virus

We previously demonstrated that short-cycle structured intermittent therapy (SIT; 7 days without therapy followed by 7 days with antiretroviral therapy [ART]) with a ritonavir-boosted, indinavir-based, twice-daily regimen maintained suppression of plasma HIV viremia while reducing serum levels of lipids. Adherence to such a regimen may be problematic for certain patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research